Literature DB >> 33193834

Combined use of thyroid stimulating hormone plus free thyroxine levels and gestational age at birth for the prediction of neonatal hypothyroidism and associated risk factors.

Junqi Li1, Jing Cheng1, Qiuyue Li2.   

Abstract

The present study aimed to explore the effectiveness of the combined use of thyroid-stimulating hormone (TSH) and free thyroxine [(FT4); TSH+FT4] levels and gestational age at birth to predict neonatal hypothyroidism and to identify the risk factors associated with the disease. The clinical data of 686 neonates with suspected hypothyroidism (TSH >10 mIU/l) who were admitted to The First Affiliated Hospital of Chongqing Medical University were retrospectively analyzed. From these, 70 neonates with confirmed hypothyroidism were assigned to the patient group and another 70 neonates with normal thyroid function to the normal (control) group. Sex, gestational age at birth, Apgar score, birth weight, body length, head circumference and heart rate data were collected. TSH and FT4 levels were measured by electrochemiluminescence immunoassay, and the predictive value of combined use of TSH+FT4 and gestational age at birth on neonatal hypothyroidism was analyzed. The prespecified secondary outcomes were the risk factors for neonatal hypothyroidism determined using univariate and logistic regression analyses. TSH levels were significantly higher, whereas FT4 levels were lower in the patient group at 3 days of age compared with the control group (P<0.05). After 8-week treatment with thyroxine, these levels were not significantly different between the patient and control groups (P<0.05). The combined use of TSH+FT4 levels and gestational age at birth to predict neonatal hypothyroidism demonstrated a significantly improved sensitivity, specificity, accuracy, positive predictive value and negative predictive value (92.86, 97.26, 96.76, 81.25 and 99.07%, respectively) compared with the use of only TSH+FT4 levels (P<0.05). Logistic regression analysis revealed a low gestational age at birth, maternal thyroid dysfunction and low birth weight were risk factors for neonatal hypothyroidism (P<0.05). The combined use of TSH+FT4 levels and gestational age at birth resulted in an improved prediction of neonatal hypothyroidism and contributed to early therapeutic intervention. Thus, special intervention is necessary for pregnant women with thyroid dysfunction to reduce the incidence of neonatal hypothyroidism.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  free thyroxine; gestational age at birth; hypothyroidism; neonate; risk factors; thyroid-stimulating hormone

Year:  2020        PMID: 33193834      PMCID: PMC7646690          DOI: 10.3892/etm.2020.9349

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  25 in total

1.  Neonatal hypothyroidism affects testicular glucose homeostasis through increased oxidative stress in prepubertal mice: effects on GLUT3, GLUT8 and Cx43.

Authors:  D Sarkar; S K Singh
Journal:  Andrology       Date:  2017-05-04       Impact factor: 3.842

2.  Intelligence Quotient at the Age of Six years of Iranian Children with Congenital Hypothyroidism.

Authors:  Khaled Rahmani; Shahin Yarahmadi; Koorosh Etemad; Yadollah Mehrabi; Nasrin Aghang; Ahmad Koosha; Hamid Soori
Journal:  Indian Pediatr       Date:  2017-09-26       Impact factor: 1.411

3.  Possible effects of neonatal vitamin B12 status on TSH-screening program: a cross-sectional study from Turkey.

Authors:  Zerrin Onal; Seda Balkaya; Atilla Ersen; Neval Mutlu; Hasan Onal; Erdal Adal
Journal:  J Pediatr Endocrinol Metab       Date:  2017-05-01       Impact factor: 1.634

4.  Prenatal Diagnosis of Fetal Goitrous Hypothyroidism in a Euthyroid Mother: A Management Challenge.

Authors:  Gabrielle Aubry; Mary Pontvianne; Marion Chesnais; Anne Sophie Weingertner; Fernando Guerra; Romain Favre
Journal:  J Ultrasound Med       Date:  2017-06-20       Impact factor: 2.153

5.  Vitamin C prevents hypothyroidism associated neuronal damage in the hippocampus of neonatal and juvenile rats: A stereological study.

Authors:  Elnaz Khordad; Fatemeh Alipour; Farimah Beheshti; Mahmoud Hosseini; Ali Akbar Rajabzadeh; Farimah Asiaei; Masoumeh Seghatoleslam
Journal:  J Chem Neuroanat       Date:  2017-11-24       Impact factor: 3.052

6.  Hexavalent Chromium Reduction by Microbacterium oleivorans A1: A Possible Mechanism of Chromate -Detoxification and -Bioremediation.

Authors:  Angana Sarkar; Pinaki Sar; Ekramul Islam
Journal:  Recent Pat Biotechnol       Date:  2016

7.  [Retrospective study on neonatal screening for congenital hypothyroidism and phenylketonuria in China in the past 22 years].

Authors:  Yan-hua Xu; Yu-feng Qin; Zheng-yan Zhao
Journal:  Zhonghua Er Ke Za Zhi       Date:  2009-01

8.  Pilot Neonatal Screening Program for Central Congenital Hypothyroidism: Evidence of Significant Detection.

Authors:  Débora Braslavsky; Maria Virginia Méndez; Laura Prieto; Ana Keselman; Rosa Enacan; Laura Gruñeiro-Papendieck; Nicolas Jullien; Alexandru Savenau; Rachel Reynaud; Thierry Brue; Ignacio Bergadá; Ana Chiesa
Journal:  Horm Res Paediatr       Date:  2017-09-12       Impact factor: 2.852

9.  Hypothyroidism in Infants With Congenital Heart Disease Exposed to Excess Iodine.

Authors:  Vidhu V Thaker; Marjorie F Galler; Audrey C Marshall; Melvin C Almodovar; Ho-Wen Hsu; Christopher J Addis; Henry A Feldman; Rosalind S Brown; Bat-Sheva Levine
Journal:  J Endocr Soc       Date:  2017-07-11

10.  The syndrome of central hypothyroidism and macroorchidism: IGSF1 controls TRHR and FSHB expression by differential modulation of pituitary TGFβ and Activin pathways.

Authors:  Marta García; Raquel Barrio; Montserrat García-Lavandeira; Angela R Garcia-Rendueles; Adela Escudero; Esther Díaz-Rodríguez; Darya Gorbenko Del Blanco; Ana Fernández; Yolanda B de Rijke; Elena Vallespín; Julián Nevado; Pablo Lapunzina; Vilborg Matre; Patricia M Hinkle; Anita C S Hokken-Koelega; María P de Miguel; José Manuel Cameselle-Teijeiro; Manuel Nistal; Clara V Alvarez; José C Moreno
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.